Skip to main content

Table 1 Patient characteristics

From: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

Patients N = 29
Median age (range) - yrs 59 (26 -- 80)
Gender -- no. (%)  
Male (%) 15 (52.0)
Female (%) 14 (48.0)
ECOG performance status -- no. (%)  
0 11 (37.9)
1 17 (58.6)
2 1 (3.5)
Primary tumor site -- no. (%)  
Pancreas 13 (44.8)
Functioning 5 (17.2)
Unknown 7 (24.2)
Small bowel 7 (24.2)
Appendix 1 (3.4)
Colon 1 (3.4)
Tumor Stage -- no. (%)  
Locally advanced/metastatic 2/27
Site of metastases -- no. (%)  
< 2 sites 13 (44.8)
≥ 2 sites 16 (55.2)
Prior therapies -- no. (%)  
Surgery 9 (31.0)
Progressive disease 29 (100)
Baseline symptoms -- no. (%)  
Diarrhea 6 (20.6)
Flushing 4 (13.8)
Carcinoid syndrome 4 (13.8)
Hypoglycemia 2 (6.9)
Others 10 (34.5)
Circulating chromogranin A levels (U/L) - no. (%)  
Normal levels 4 (13.8)
Supranormal levels 25 (86.2)
Histological tumor characteristics -- no. (%)
SST2
 
1+ 2 (9.1)
2+ 8 (36.4)
3+ 12 (54.5)
missing 7
Mitosis (per square millimeter)  
< 2 17 (68.0)
2 -- 20 7 (28.0)
> 20 1 (4.0)
missing 4
Ki67  
≤ 2% 11 (42.3)
3 -- 10% 13 (50.0)
> 10% 2 (7.7)
missing 3
VEGF  
0 3 (15.8)
1 4 (21.1)
2 7 (36.8)
3 5 (26.8)
missing 10
  1. SST2 = somatostatin receptor type 2
  2. VEGF = vascular endothelial growth factor